AstraZeneca's Fasenra Treatment Passed One of Two Endpoints in Trial
25 Ottobre 2022 - 8:47AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Tuesday that a Phase 3 trial of its Fasenra
treatment for eosinophilic esophagitis passed one dual-primary
endpoint but failed the other.
The Anglo-Swedish pharma giant said the results from the trial
showed Fasenra made a statistically significant improvement in
histological disease remission, but didn't change dysphagia
symptoms compared to a placebo, when tested in patients with
eosinophilic esophagitis.
The drug was tested in a double-blind, placebo-controlled trial
of 210 patients with eosinophilic esophagitis, a rare, progressive,
chronic inflammatory disease of the esophagus.
The safety and tolerability of the drug was consistent with the
known profile of the medicine.
"The results from the MESSINA Phase 3 trial in eosinophilic
esophagitis confirm that Fasenra achieved near complete depletion
of tissue eosinophils, consistent with its mechanism of action,
however this did not translate into an improvement in dysphagia
symptoms," said Mene Pangalos, executive vice president of
BioPharmaceuticals R&D at AstraZeneca.
The company will continue to analyze the dataset.
Fasenra is currently approved as an add-on maintenance treatment
for severe eosinophilic asthma in the U.S., European Union, Japan
and other countries.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
October 25, 2022 02:32 ET (06:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
